Breaking News

Isis Earns Biogen Milestone

August 15, 2014

Advances ISIS-SMN Rx in Spinal Muscular Atrophy

Isis Pharmaceuticals has earned a $2 million milestone payment from Biogen Idec for the advancement of the ongoing study of ISIS-SMNRx in children with spinal muscular atrophy (SMA). 

The FDA has granted orphan drug status and fast track designation to ISIS-SMNRx for the treatment of SMA. Isis and Biogen are collaborating to develop and potentially commercialize the investigational compound to treat all types of SMA. 

Under the January 2012 agreement, Isis is responsible for global development and Biogen has the option to license the compound until the first successful Phase II/III study or the completion of two Phase II/III studies.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.